Search Results - "Vallon‐Christersson, J."

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML by Lindblad, O, Cordero, E, Puissant, A, Macaulay, L, Ramos, A, Kabir, N N, Sun, J, Vallon-Christersson, J, Haraldsson, K, Hemann, M T, Borg, Å, Levander, F, Stegmaier, K, Pietras, K, Rönnstrand, L, Kazi, J U

“…Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always…”
Get full text

Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative by Rydén, L., Loman, N., Larsson, C., Hegardt, C., Vallon‐Christersson, J., Malmberg, M., Lindman, H., Ehinger, A., Saal, L. H., Borg, Å.

“…Background Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are…”
Get full text

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families by VALLON-CHRISTERSSON, Johan, CAYANAN, Charmagne, BORG, Ake, MONTEIRO, Alvaro N. A, HARALDSSON, Karin, LOMAN, Niklas, BERGTHORSSON, Jon Thor, BRØNDUM-NIELSEN, Karen, GERDES, Anne-Marie, MØLLER, Pal, KRISTOFFERSSON, Ulf, OLSSON, Hakan

“…Germline mutations in the breast and ovarian cancer susceptibility gene BRCA1 are responsible for the majority of cases involving hereditary breast and ovarian…”
Get full text

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic by Winter, C., Nilsson, M.P., Olsson, E., George, A.M., Chen, Y., Kvist, A., Törngren, T., Vallon-Christersson, J., Hegardt, C., Häkkinen, J., Jönsson, G., Grabau, D., Malmberg, M., Kristoffersson, U., Rehn, M., Gruvberger-Saal, S.K., Larsson, C., Borg, Å., Loman, N., Saal, L.H.

“…A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and…”
Get full text

A prospective cohort study identifying radiologic and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy by Gulis, K., Ellbrant, J., Svensjö, T., Skarping, I., Vallon-Christersson, J., Loman, N., Bendahl, P.O., Rydén, L.

“…Neoadjuvant chemotherapy (NAC) is an established treatment option for early breast cancer, potentially downstaging the tumor and increasing the eligibility for…”
Get full text

287P Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer by Staaf, J., Veerla, S., Hohmann, L., Nacer, D.F., Vallon-Christersson, J.

Get full text

2333P Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers by Karlsson, A., Killander, F., Nacer, D.F., Häkkinen, J., Rosengren, F., Vallon-Christersson, J., Staaf, J.

Get full text

17P Clinicopathological and transcriptomic characterization of luminal HER2-enriched breast cancer by Hohmann, L., Oliveira, D., Sigurjónsdóttir, K., Bosch, A., Borg, Å., Vallon-Christersson, J., Staaf, J.

Get full text

150P Molecular characteristics of breast cancer patients subjected to screening for germline predisposition in a population-based observational study by Staaf, J., Oliveira, D., Vallon-Christersson, J., Ehrencrona, H., Kvist, A., Borg, Å.

Get full text

The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective series by Møller, P., Borg, A., Heimdal, K., Apold, J., Vallon-Christersson, J., Hovig, E., Mæhle, L.

“…Inherited breast cancer is a heterogenous group of diseases. We examined this heterogeneity in a prospective series of inherited breast and ovarian cancers,…”
Get full text

316P Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer by Hohmann, L., Sigurjónsdóttir, K., Bosch, A., Nacer, D.F., Veerla, S., Häkkinen, J., Vallon-Christersson, J., Borg, Å., Memari, Y., Davies, H., Nik-Zainal, S., Staaf, J.

Get full text

Transcriptional intra-tumour heterogeneity predicted by deep learning in routine breast histopathology slides provides independent prognostic information by Wang, Yinxi, Ali, Maya Alsheh, Vallon-Christersson, Johan, Humphreys, Keith, Hartman, Johan, Rantalainen, Mattias

“…Intra-tumour heterogeneity (ITH) causes diagnostic challenges and increases the risk for disease recurrence. Quantification of ITH is challenging and has not…”
Get full text

50P HER2/HER3 heterodimerization can define ER+/HER2-low breast cancer as a distinct biological entity by Sigurjónsdóttir, K., Ngoc, P.C.T., Vallon-Christersson, J., Bosch, A.

Get full text

52P RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer by Vallon-Christersson, J., Staaf, J., Häkkinen, J., Hegardt, C., Saal, L., Ehinger, A., Larsson, C., Loman, N., Rydén, L., Malmberg, M., Borg, Å.

Get full text

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers by Glodzik, Dominik, Bosch, Ana, Hartman, Johan, Aine, Mattias, Vallon-Christersson, Johan, Reuterswärd, Christel, Karlsson, Anna, Mitra, Shamik, Niméus, Emma, Holm, Karolina, Häkkinen, Jari, Hegardt, Cecilia, Saal, Lao H., Larsson, Christer, Malmberg, Martin, Rydén, Lisa, Ehinger, Anna, Loman, Niklas, Kvist, Anders, Ehrencrona, Hans, Nik-Zainal, Serena, Borg, Åke, Staaf, Johan

“…Homologous recombination deficiency (HRD) is a defining characteristic in BRCA -deficient breast tumors caused by genetic or epigenetic alterations in key…”
Get full text

Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype by Holmquist-Mengelbier, Linda, Fredlund, Erik, Löfstedt, Tobias, Noguera, Rosa, Navarro, Samuel, Nilsson, Helén, Pietras, Alexander, Vallon-Christersson, Johan, Borg, Åke, Gradin, Katarina, Poellinger, Lorenz, Påhlman, Sven

“…In neuroblastoma specimens, HIF-2α but not HIF-1α is strongly expressed in well-vascularized areas. In vitro, HIF-2α protein was stabilized at 5% O 2…”
Get full text

Molecular analyses of triple-negative breast cancer in the young and elderly by Aine, Mattias, Boyaci, Ceren, Hartman, Johan, Häkkinen, Jari, Mitra, Shamik, Campos, Ana Bosch, Nimeus, Emma, Ehinger, Anna, Vallon-Christersson, Johan, Borg, Åke, Staaf, Johan

“…Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because…”
Get full text

Abstract PD2-08: Predictors of axillary nodal metastasis based on gene expression and clinicopathological characteristics: Data from a population-based prospective study, the Sweden Cancerome Analysis Network – Breast (SCAN-B) by Dihge, L, Staaf, J, Vallon-Christersson, J, Hegardt, C, Häkkinen, J, Borg, Å, Rydén, L

“…Abstract Background Gene expression patterns show promise in estimating prognosis and directing adjuvant therapy, but its significance in guiding axillary…”
Get full text

Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer by Sharma, Abhinav, Weitz, Philippe, Wang, Yinxi, Liu, Bojing, Vallon-Christersson, Johan, Hartman, Johan, Rantalainen, Mattias

“…Histological grade is a well-known prognostic factor that is routinely assessed in breast tumours. However, manual assessment of Nottingham Histological Grade…”
Get full text

24P Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancer by Karlsson, A., Killander, F., Oliveira, D.F.N., Rosengren, F., Vallon-Christersson, J., Staaf, J.

Get full text